Trials in California.
225 APOE4-relevant Alzheimer’s trials run in California — 100 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Non-carriers only, not for APOE4NCT00574132Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…
- Drug trial for diagnosed APOE4 carriersNCT00575055Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- APOE4/4 only, closed to new enrolleesNCT06304883Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
This is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…
- Drug trial for symptomatic early Alzheimer'sNCT06335173A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
This trial tests sabirnetug, an antibody given by IV infusion every four weeks, against placebo. It looks at whether the drug slows decline in thinking and…
- Directly recruits APOE4 carriersNCT07447206Vascular Intervention Strategies Trial for Alzheimer's
This small pilot study tests whether a pharmacist-led program can manage high blood pressure and high cholesterol in 10 people. Everyone takes an angiotensin…
- Exclusively recruits APOE4 carriersNCT07516119Predicting Pre-dementia
This observational study is testing whether a multimodal prediction model — combining genetic risk scores, blood biomarkers, health record data, and wearable…
- Exclusively recruits APOE4 carriersNCT07646054Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers
This trial is testing whether a year-long digital lifestyle coaching program can improve blood-based markers linked to Alzheimer's risk. Twelve hundred…
- 4/4 carriers excluded, one copy may qualifyNCT07688213A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing SAR448851, a once-daily oral pill, in people with early Alzheimer's disease who have confirmed amyloid buildup in the brain.…
- General AD trial, no APOE4 focusNCT00265148Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
This Phase 2 trial tested rosiglitazone, a drug originally developed for type 2 diabetes, against a placebo in people with mild to moderate Alzheimer's…
- APOE4 enrolled, response may differNCT00348140Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
- Enrolled carriers, prior data unfavorableNCT00348309Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
- APOE4 stratified, suggests less benefitNCT00428090Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…
- Closed trial, APOE4 stratifiedNCT00550420Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
This Phase 3 trial tested rosiglitazone XR, a diabetes drug, in people with mild-to-moderate Alzheimer's disease. It was an open-label extension study, meaning…
- Drug trial, genotype not specified in sourceNCT00667810Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. It looked at how well the…
- Drug trial, not APOE4-specific, carriers at riskNCT00676143Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. Researchers measured safety…
- Open to carriers, not 4-specificNCT00710684A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
This trial tested SB-742457, an experimental drug added on top of donepezil, the standard Alzheimer's medication, in people with mild-to-moderate Alzheimer's…
- Drug extension study, prior participants onlyNCT00998764A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
This trial looked at the long-term safety and tolerability of bapineuzumab, an antibody drug given by infusion, in people with Alzheimer's who had finished an…
- Cancer trial, not for healthy carriersNCT01227954Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
This trial tests whether a more precise form of whole-brain radiation can spare the hippocampus, the brain's memory center, in people whose cancer has spread…
- Not APOE4-related; rare VCP gene studyNCT01353430Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
This is a research study, not a drug trial. Investigators are collecting blood, urine, family histories and questionnaires from families with a rare inherited…
- Huntington's study, not about APOE4NCT01574053Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll-HD is an observational study, meaning no drug or treatment is given. It follows people with Huntington's disease, and their relatives and controls,…
- Surgery study, genotype not specifiedNCT01606488Effects of Brain Beta-Amyloid on Postoperative Cognition
This study uses a brain scan with a tracer called florbetapir to check for amyloid plaques before hip or knee replacement surgery. Researchers then track…
- Not for APOE4 carriers; mutation carriers onlyNCT01760005Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
This trial tests several investigational drugs, including gantenerumab, solanezumab, E2814 and lecanemab, against placebo. It asks whether they slow cognitive…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Not Alzheimer's-focused, not APOE4-specificNCT02327845Phenotype, Genotype & Biomarkers in ALS and Related Disorders
This is an observational study, so nothing is being tested as a treatment. Researchers are looking at how the genes and symptoms of ALS and related conditions,…
- Observational depression study, not APOE4-specificNCT02434393Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project
This observational study follows older adults with late life depression to understand why some develop memory and thinking problems faster. Participants get…
- Open to carriers, not 4-specificNCT02814526Exercise in Adults With Mild Memory Problems
This trial tests whether aerobic exercise (like treadmill walking) does more for brain health than stretching and balance routines in older adults with mild…
- Heart trial, genotype not relevantNCT02884206Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
- Observational only, no treatment involvedNCT02951598A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
- Discontinued trial, not APOE4-specificNCT02972658A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
- Cancer patients only, genotype not specifiedNCT03016741Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
This trial is studying whether prostate cancer hormone therapies — specifically abiraterone acetate and enzalutamide — affect brain structure and cognitive…
- Unrelated to APOE4 or Alzheimer'sNCT03047369The Myelin Disorders Biorepository Project
This is a biorepository project, not a treatment trial. Researchers are collecting medical records and biological samples (like blood or tissue) from people…
- Open to carriers, not 4-specificNCT03108846Escitalopram for Agitation in Alzheimer's Disease
This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…
- Not relevant: ALS records study, no APOE4NCT03489278Clinical Procedures to Support Research in ALS
This study uses information already in the medical records of people with ALS and related conditions to learn more about those diseases. It tests no drug or…
- Open to carriers, not 4-specificNCT03507257Longitudinal Early-onset Alzheimer's Disease Study Protocol
LEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…
- Designed specifically around APOE4 carriersNCT03613844DHA Brain Delivery Trial
This trial is testing whether APOE4 carriers absorb less DHA (an omega-3 fatty acid) into the brain compared to non-carriers, and whether DHA supplements can…
- Open registry, genotype not requiredNCT03638583Alzheimer Prevention Trials (APT) Webstudy
The APT Webstudy is not a treatment trial. It is an online registry that tracks cognitive health over time in people 50 and older who do not have dementia. The…
- Open to carriers, not 4-specificNCT03703856Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
This trial is testing memantine, an FDA-approved Alzheimer's medication, to understand which patients respond to it best by tracking brain function and symptom…
- Open to carriers, genotype not requiredNCT03860857Biomarker Exploration in Aging, Cognition and Neurodegeneration
This observational study is tracking brain changes in people 60 and older who currently have normal cognition. Researchers are using MRI, amyloid PET, tau PET,…
- Open to carriers, not 4-specificNCT03881579Supportive Care for Cognitively Impaired Patients and Families
This trial tests whether a year-long nurse-led palliative care program improves quality of life and reduces healthcare use for people living with dementia or…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- Open to carriers, genotype not trackedNCT04098666Metformin in Alzheimer's Dementia Prevention
This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…
- Open to carriers, genotype not requiredNCT04100057Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia
This trial tests whether treating insomnia with Cognitive Behavioral Therapy for Insomnia (CBT-I) reduces anxiety, depression, agitation, and other behavioral…
- Huntington's trial, not relevant to APOE4NCT04120493Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
This trial tests AMT-130, a gene therapy delivered by brain surgery into a deep brain region called the striatum, in adults with early Huntington's disease. It…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.